ABCB4: Insights from pathobiology into therapy

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 5, 2014, Pages 557-563

  Falguières, Thomas ^a,b   Aït Slimane, Tounsia ^a,b   Housset, Chantal ^a,b,c   Maurice, Michèle ^a,b  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; FARNESOID X RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 3; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE; URSODEOXYCHOLIC ACID; MULTIDRUG RESISTANCE PROTEIN;

BILE; CLINICAL TRIAL (TOPIC); GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC VARIABILITY; HEPATOCYTE TRANSPLANTATION; HETEROZYGOTE; HISTORY; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER CELL MEMBRANE; LIVER DISEASE; LIVER TRANSPLANTATION; MICELLE; MULTIDRUG RESISTANCE GENE 3; NONHUMAN; PATHOLOGY; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SHORT SURVEY; SOLUBILIZATION; ANIMAL; DEFICIENCY; DEFICIENCY DISEASES; GENETICS; MUTATION; PHYSIOLOGY;

ANIMALS; DEFICIENCY DISEASES; HUMANS; MUTATION; P-GLYCOPROTEINS;

EID: 84912567019     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.03.001     Document Type: Short Survey

References (80)

1. Boyer J.L. Bile formation and secretion. Compr Physiol 2013, 3:1035-1078.
2. Admirand W.H., Small D.M. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 1968, 47:1043-1052.
3. Hofmann A.F., Small D.M. Detergent properties of bile salts: correlation with physiological function. Annu Rev Med 1967, 18:333-376.
4. Wang D.Q., Cohen D.E., Carey M.C. Biliary lipids and cholesterol gallstone disease. J Lipid Res 2009, 50(Suppl.):S406-S411.
5. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., Houwen R.H. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010, 52:258-271.
6. Jacquemin E., De Vree J.M., Cresteil D., Sokal E.M., Sturm E., Dumont M., et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001, 120:1448-1458.
7. Rosmorduc O., Hermelin B., Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120:1459-1467.
8. Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J., Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125:452-459.
9. Ziol M., Barbu V., Rosmorduc O., Frassati-Biaggi A., Barget N., Hermelin B., et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008, 135:131-141.
10. Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010, 30:134-146.
11. Geenes V., Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009, 15:2049-2066.
12. Erlinger S. Low phospholipid-associated cholestasis and cholelithiasis. Clin Res Hepatol Gastroenterol 2012, 36(Suppl. 1):S36-S40.
13. Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25:519-523.
14. Van der Bliek A.M., Baas F., Ten Houte de Lange T., Kooiman P.M., Van der Velde-Koerts T., Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 1987, 6:3325-3331.
15. van der Bliek A.M., Kooiman P.M., Schneider C., Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988, 71:401-411.
16. Lincke C.R., Smit J.J., van der Velde-Koerts T., Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 1991, 266:5303-5310.
17. Smith A.J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000, 275:23530-23539.
18. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
19. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77:1071-1081.
20. Smith A.J., Timmermans-Hereijgers J.L., Roelofsen B., Wirtz K.W., van Blitterswijk W.J., Smit J.J., et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994, 354:263-266.
21. Smit J.J., Schinkel A.H., Mol C.A., Majoor D., Mooi W.J., Jongsma A.P., et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994, 71:638-649.
22. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
23. Zolnerciks J.K., Andress E.J., Nicolaou M., Linton K.J. Structure of ABC transporters. Essays Biochem 2011, 50:43-61.
24. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
25. Oude Elferink R.P., Tytgat G.N., Groen A.K. Hepatic canalicular membrane 1: the role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J 1997, 11:19-28.
26. Crawford J.M., Mockel G.M., Crawford A.R., Hagen S.J., Hatch V.C., Barnes S., et al. Imaging biliary lipid secretion in the rat: ultrastructural evidence for vesiculation of the hepatocyte canalicular membrane. J Lipid Res 1995, 36:2147-2163.
27. Morita S.Y., Kobayashi A., Takanezawa Y., Kioka N., Handa T., Arai H., et al. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 2007, 46:188-199.
28. Karpen S.J. Nuclear receptor regulation of hepatic function. J Hepatol 2002, 36:832-850.
29. Chianale J., Vollrath V., Wielandt A.M., Amigo L., Rigotti A., Nervi F., et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996, 314:781-786.
30. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompson J.R., et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003, 278:51085-51090.
31. Shoda J., Okada K., Inada Y., Kusama H., Utsunomiya H., Oda K., et al. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007, 37:548-556.
32. Francis G.A., Fayard E., Picard F., Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65:261-311.
33. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276:28857-28865.
34. Li F., Patterson A.D., Krausz K.W., Tanaka N., Gonzalez F.J. Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis. J Lipid Res 2012, 53:1625-1635.
35. Hooiveld G.J., Vos T.A., Scheffer G.L., Van Goor H., Koning H., Bloks V., et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 1999, 117:678-687.
36. Ganne-Carrie N., Baussan C., Grando V., Gaudelus J., Cresteil D., Jacquemin E. Progressive familial intrahepatic cholestasis type 3 revealed by oral contraceptive pills. J Hepatol 2003, 38:693-694.
37. Poupon R., Rosmorduc O., Boelle P.Y., Chretien Y., Corpechot C., Chazouilleres O., et al. Genotype-phenotype relationships in the low-phospholipid associated cholelithiasis syndrome. A study of 156 consecutive patients. Hepatology 2013, 58:1105-1110.
38. Kipp H., Arias I.M. Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J Biol Chem 2000, 275:15917-15925.
39. Kipp H., Arias I.M. Trafficking of canalicular ABC transporters in hepatocytes. Annu Rev Physiol 2002, 64:595-608.
40. Aït-Slimane T., Trugnan G., Van I.S.C., Hoekstra D. Raft-mediated trafficking of apical resident proteins occurs in both direct and transcytotic pathways in polarized hepatic cells: role of distinct lipid microdomains. Mol Biol Cell 2003, 14:611-624.
41. Ortiz D.F., Moseley J., Calderon G., Swift A.L., Li S., Arias I.M. Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J Biol Chem 2004, 279:32761-32770.
42. Chan W., Calderon G., Swift A.L., Moseley J., Li S., Hosoya H., et al. Myosin II regulatory light chain is required for trafficking of bile salt export protein to the apical membrane in Madin-Darby canine kidney cells. J Biol Chem 2005, 280:23741-23747.
43. Ikebuchi Y., Takada T., Ito K., Yoshikado T., Anzai N., Kanai Y., et al. Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4. Hepatol Res 2009, 39:1091-1107.
44. Lam P., Xu S., Soroka C.J., Boyer J.L. A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis. Hepatology 2012, 55:1901-1911.
45. Swiatecka-Urban A., Duhaime M., Coutermarsh B., Karlson K.H., Collawn J., Milewski M., et al. PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 2002, 277:40099-40105.
46. Li M., Wang W., Soroka C.J., Mennone A., Harry K., Weinman E.J., et al. NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function. J Biol Chem 2010, 285:19299-19307.
47. Deleuze J.F., Jacquemin E., Dubuisson C., Cresteil D., Dumont M., Erlinger S., et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996, 23:904-908.
48. Carey M.C., Small D.M. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest 1978, 61:998-1026.
49. Degiorgio D., Colombo C., Seia M., Porcaro L., Costantino L., Zazzeron L., et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet 2007, 15:1230-1238.
50. Poupon R., Barbu V., Chamouard P., Wendum D., Rosmorduc O., Housset C. Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3. Liver Int 2010, 30:327-331.
51. Colombo C., Vajro P., Degiorgio D., Coviello D.A., Costantino L., Tornillo L., et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 2011, 52:73-83.
52. Giovannoni I., Santorelli F.M., Candusso M., Di Rocco M., Bellacchio E., Callea F., et al. Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. Dig Liver Dis 2011, 43:567-570.
53. Fang L.J., Wang X.H., Knisely A.S., Yu H., Lu Y., Liu L.Y., et al. Chinese children with chronic intrahepatic cholestasis and high gamma-glutamyl transpeptidase: clinical features and association with ABCB4 mutations. J Pediatr Gastroenterol Nutr 2012, 55:150-156.
54. Keitel V., Burdelski M., Warskulat U., Kuhlkamp T., Keppler D., Haussinger D., et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41:1160-1172.
55. Keitel V., Vogt C., Haussinger D., Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006, 131:624-629.
56. Dzagania T., Engelmann G., Haussinger D., Schmitt L., Flechtenmacher C., Rtskhiladze I., et al. The histidine-loop is essential for transport activity of human MDR3. A novel mutation of MDR3 in a patient with progressive familial intrahepatic cholestasis type 3. Gene 2012, 506:141-145.
57. Wendum D., Barbu V., Rosmorduc O., Arrive L., Flejou J.F., Poupon R. Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch 2012, 460:291-298.
58. Dixon P.H., Weerasekera N., Linton K.J., Donaldson O., Chambers J., Egginton E., et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000, 9:1209-1217.
59. Delaunay J.L., Durand-Schneider A.M., Delautier D., Rada A., Gautherot J., Jacquemin E., et al. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology 2009, 49:1218-1227.
60. Gautherot J., Durand-Schneider A.M., Delautier D., Delaunay J.L., Rada A., Gabillet J., et al. Effects of cellular, chemical and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporters ABCB1/ABCB4. J Biol Chem 2012, 287:5070-5078.
61. Degiorgio D., Corsetto P.A., Rizzo A.M., Colombo C., Seia M., Costantino L., et al. Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction. Eur J Hum Genet 2013, [in press]. 10.1038/ejhg.2013.214.
62. Andress E.J., Nicolaou M., Romero M.R., Naik S., Dixon P.H., Williamson C., et al. A molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4. Hepatology 2013, [in press]. 10.1002/hep.26970.
63. EASL EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
64. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36(Suppl. 1):S3-S12.
65. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
66. -/- mice. Hepatology 2009, 49:1972-1981.
67. Fickert P., Pollheimer M.J., Silbert D., Moustafa T., Halilbasic E., Krones E., et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013, 58:1201-1208.
68. Kok T., Bloks V.W., Wolters H., Havinga R., Jansen P.L., Staels B., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003, 369:539-547.
69. Nakamuta M., Fujino T., Yada R., Yasutake K., Yoshimoto T., Harada N., et al. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010, 48:22-28.
70. Ghonem N.S., Ananthanarayanan M., Soroka C.J., Boyer J.L. PPARalpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 2014, 59:1030-1042.
71. Caroli-Bosc F.X., Le Gall P., Pugliese P., Delabre B., Caroli-Bosc C., Demarquay J.F., et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001, 46:540-544.
72. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45:3569-3572.
73. Gonzales E., Grosse B., Cassio D., Davit-Spraul A., Fabre M., Jacquemin E. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol 2012, 57:695-698.
74. Rowe S.M., Verkman A.S. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013, 3:a009761.
75. Pedemonte N., Lukacs G.L., Du K., Caci E., Zegarra-Moran O., Galietta L.J., et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005, 115:2564-2571.
76. Van Goor F., Straley K.S., Cao D., Gonzalez J., Hadida S., Hazlewood A., et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1117-L1130.
77. Odolczyk N., Fritsch J., Norez C., Servel N., da Cunha M.F., Bitam S., et al. Discovery of novel potent DeltaF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med 2013, 5:1484-1501.
78. Amaral M.D., Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007, 28:334-341.
79. De Vree J.M., Ottenhoff R., Bosma P.J., Smith A.J., Aten J., Oude Elferink R.P. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000, 119:1720-1730.
80. Prickett M., Jain M. Gene therapy in cystic fibrosis. Transl Res 2013, 161:255-264.